UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Renal manifestations in inflammatory bowel disease: a systematic review

Journal of gastroenterology, 2022-09, Vol.57 (9), p.619-629

2022

Volltextzugriff (PDF)

Faecal microbiota transplantation in children: A systematic review

Acta Paediatrica, 2024-09, Vol.113 (9), p.1991-2002

2024

Volltextzugriff (PDF)

Nausea is the only symptom associated with delayed gastric emptying in pediatric functional dyspepsia patients

Neurogastroenterology and motility, 2023-09, Vol.35 (9), p.e14620-n/a

2023

Volltextzugriff (PDF)

Nutritional management of high‐output ileostomies in paediatric patients is vital and more evidence‐based guidelines are needed

Acta Paediatrica, 2024-05, Vol.113 (5), p.861-870

2024

Volltextzugriff (PDF)

Identifying risk factors of anti‐TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease

Journal of pediatric gastroenterology and nutrition, 2024-01, Vol.78 (1), p.95-104

2024

Volltextzugriff (PDF)

Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease

Journal of pediatric gastroenterology and nutrition, 2019-06, Vol.68 (6), p.847-853

2019

Volltextzugriff (PDF)

A validity framework for accountability: educational measurement and language testing

Language Testing in Asia, 2022-02, Vol.12 (1), p.1-14, Article 3

Hoeve, Karen B.

2022

Volltextzugriff (PDF)

Practice Analysis: Developing a Content Outline for the Child Abuse Pediatrics Certification Exam

Child maltreatment, 2024-07, p.10775595241268169

2024

Volltextzugriff (PDF)

Occurrence of atypical HUS associated with influenza B

European journal of pediatrics, 2017-04, Vol.176 (4), p.449-454

2017

Volltextzugriff (PDF)

Liver involvement in kidney disease and vice versa

Pediatric nephrology (Berlin, West), 2018-06, Vol.33 (6), p.957-971

2018

Volltextzugriff (PDF)

Intractable hiccups as a presenting feature of clinically isolated syndrome

Journal of pediatric neurology, 2014, Vol.12 (1), p.49-53

2014

Volltextzugriff (PDF)

Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study

Pediatric nephrology (Berlin, West), 2018-11, Vol.33 (11), p.2085-2093

2018

Volltextzugriff (PDF)

Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease

Expert opinion on drug safety, 2018-02, Vol.17 (2), p.185-196

2018

Volltextzugriff (PDF)

Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place

Paediatric drugs, 2020-10, Vol.22 (5), p.449-461

2020

Volltextzugriff (PDF)

Su1791 – Longterm Outcome of Pediatric Patients with Inflammatory Bowel Disease Treated with Immunomodulators

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-612-S-613

2019

Volltextzugriff (PDF)

Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2018-11, Vol.12 (11), p.1316-1325

2018

Volltextzugriff (PDF)

Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy

The Journal of pediatrics, 2022-01, Vol.240, p.150-157.e4

2022

Volltextzugriff (PDF)

Mo1896 INFLIXIMAB SERUM LEVELS DURING INDUCTION PREDICT LONG-TERM ENDOSCOPIC REMISSION IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-968-S-968

2020

Volltextzugriff (PDF)

Child with protein losing enteropathy as presentation of collagenous duodenitis and eosinophilic gastroenteritis

Acta gastro-enterologica belgica, 2023-04, Vol.86 (2), p.363-366

2023

Volltextzugriff (PDF)

Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease

Therapeutic drug monitoring, 2019-06, Vol.41 (3), p.317-324

2019

Volltextzugriff (PDF)

A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases

Journal of Crohn's and colitis, 2023-06, Vol.17 (6), p.896-908

2023

Volltextzugriff (PDF)

879 – Switching from Infliximab Originator to a Biosimilar Does Not Affect Pharmacokinetics, Immunogenicity and Efficacy in Pediatric Patients with Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-199-S-199

2019

Volltextzugriff (PDF)

Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel disease

Digestive and liver disease, 2020-02, Vol.52 (2), p.164-172

2020

Volltextzugriff (PDF)

Tu1868 - Infliximab Trough Levels after Induction Therapy: A Predictive Factor for Outcome in Pediatric Patients with Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-1042-S-1043

2018

Volltextzugriff (PDF)

Tu1867 - Clinical use of Infliximab Trough Levels During Maintenance in Pediatric Patients with Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-1042-S-1042

2018

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(48)
Dissertationen
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(32)
Life Sciences & Biomedicine
(31)
Humans
(20)
Child
(13)
Pediatrics
(12)
Female
(11)
Gastroenterology & Hepatology
(10)
Inflammatory Bowel Disease
(10)
Male
(9)
Children
(7)
Infliximab
(7)
Adolescent
(6)
Inflammatory Bowel Diseases - Drug Therapy
(6)
Medicine
(6)
Adult
(5)
Colitis, Ulcerative - Drug Therapy
(5)
Medicine & Public Health
(5)
Risk Factors
(5)
Treatment Outcome
(5)
Crohn Disease - Drug Therapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Renal manifestations in inflammatory bowel disease: a systematic review

Faecal microbiota transplantation in children: A systematic review

Nausea is the only symptom associated with delayed gastric emptying in pediatric functional dyspepsia patients

Nutritional management of high‐output ileostomies in paediatric patients is vital and more evidence‐based guidelines are needed

Identifying risk factors of anti‐TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease

Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease

A validity framework for accountability: educational measurement and language testing

Practice Analysis: Developing a Content Outline for the Child Abuse Pediatrics Certification Exam

Occurrence of atypical HUS associated with influenza B

Liver involvement in kidney disease and vice versa

Intractable hiccups as a presenting feature of clinically isolated syndrome

Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study

Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease

Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place

Su1791 – Longterm Outcome of Pediatric Patients with Inflammatory Bowel Disease Treated with Immunomodulators

Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease

Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy

Mo1896 INFLIXIMAB SERUM LEVELS DURING INDUCTION PREDICT LONG-TERM ENDOSCOPIC REMISSION IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Child with protein losing enteropathy as presentation of collagenous duodenitis and eosinophilic gastroenteritis

Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease

A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases

879 – Switching from Infliximab Originator to a Biosimilar Does Not Affect Pharmacokinetics, Immunogenicity and Efficacy in Pediatric Patients with Inflammatory Bowel Disease

Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel disease

Tu1868 - Infliximab Trough Levels after Induction Therapy: A Predictive Factor for Outcome in Pediatric Patients with Inflammatory Bowel Disease

Tu1867 - Clinical use of Infliximab Trough Levels During Maintenance in Pediatric Patients with Inflammatory Bowel Disease

Suchergebnisse filtern